Alectinib in Resected <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

Abstract

Among patients with resected <i>ALK</i>-positive NSCLC of stage IB, II, or IIIA, adjuvant alectinib significantly improved disease-free survival as compared with platinum-based chemotherapy. (Funded by F. Hoffmann-La Roche; ALINA ClinicalTrials.gov number, NCT03456076.).